Shorter All-Oral Regimens for Drug-Resistant Tuberculosis: A Narrative Review of Epidemiology, Trial Evidence, and Implementation, with Reference to Uzbekistan
Abstract
This narrative review summarizes selected evidence on drug-resistant tuberculosis and the 6-month all-oral regimen of bedaquiline, pretomanid, linezolid, and moxifloxacin recommended by the World Health Organization. It covers global burden estimates, the TB-PRACTECAL randomized trial, an operational cohort in routine care in Uzbekistan and Belarus, and a trial of linezolid dosing. Unfavorable outcomes and serious adverse events were much less frequent with the short regimen than with standard care in the trial, and treatment success in routine care was high. The evidence is encouraging but limited in size and in comparative data, and success depends on rapid testing, drug supply, and toxicity monitoring. Some national figures come from news summaries and should be checked against WHO sources. Figures are quoted as reported; no data were pooled. This is a non-peer-reviewed preprint. An AI assistant was used to support literature searching and drafting, and the author is responsible for the final text.
Read the paper
Related studies
- Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents
- Exploring the inhibitory performance of expired moxifloxacin and norfloxacin on copper corrosion in saline environment
- Molecular investigation of antimicrobial peptides against Helicobacter pylori proteins using a peptide-protein docking approach
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis through in silico, in vitro, and in vivo approaches
- Synthesis, Characterization, Anticancer, Antioxidant, and In Silico Evaluation of Semicarbazides and Thiosemicarbazides
- Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.